BANZEL is indicated for adjunctive treatment of seizures associated with
Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older,
and in adults.
*Eligible patients pay the first $25 and Eisai Inc. will pay up to $275 per month.
Patients can activate or register a card online at www.BanzelCard.com or by calling 1-855-EISAI-4-U
*Restrictions apply. Not available to patients enrolled in federal or state healthcare program, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE programs. Complete terms and conditions available at www.BanzelCard.com.
Support Savings Card enrollment for eligible patients and provide Patient Assistance Program (PAP) information for eligible patients. ►
Required steps identified and proper forms provided.►
Insurance-specific requirements verified plus resources and sample templates available. Process monitored and results communicated. ►
Learn about the efficacy of BANZEL® (rufinamide) in the pivotal trial
Register now to receive updates and resources
Take part in this peer-to-peer program